2026 IMS ORAL PRESENTATION: INNOVENT ANNOUNCES UPDATED PHASE 1 CLINICAL DATA OF TRISPECIFIC ANTIBODY IBI3003 (GPRC5D/BCMA/CD3) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Reuters · 2d ago

Please log in to view news